you can't always get what you need

11.30.2005

Cris Kerr highlights Naltrexone in her latest issue of 'Case Health - Health Success Stories'.

Naltrexone is traditionally used to help people who have a narcotic or alcohol addiction stay drug free. Naltrexone is used after the patient has stopped taking drugs or alcohol. It works by blocking the effects of narcotics or by decreasing the craving for alcohol. U.S. National Library of Medicine

Cris recently became aware of a drug that appeared to stop the progression of Multiple Sclerosis, potentially enhancing the quality of life of many Multiple Sclerosis (MS) sufferers.

The drug is Naltrexone (also known as ReVia) and Cris's 'Health Success Stories' database contains a growing body of compelling anecdotal evidence that Low Dose Naltrexone (LDN) works, and; it works well - BUT, sufferers can't get it.

"Naltrexone has not achieved mainstream acceptance as a treatment option for MS due to absence of clinical trial data. Research, drug development, and clinical trials are commercially-driven by sponsors. That's okay, but there's no recognized body that can officially step up to the plate to speak and act on behalf of patients. I know this because I've tried, without success, to find an authority that is sanctioned to do so."

The present system is inequitable. It doesn't place sufficient value on patient health success stories. It doesn't place sufficient value on advocating for the patient. It doesn't place sufficient value on patient-driven research or clinical trials. If it did, there would be a body sanctioned to speak and act on a promising body of patient testimonials.

How many stories similar to the LDN story are out there? We don't know, because they haven't all been collected, stored, and shared. That makes me feel uneasy and should make you feel uneasy.

We need an organisation chartered to act on this type of evidence; an organisation that values patient testimony and can make recommendations (without prejudice) on behalf of patients from all corners of the globe.

0 comments: